Report results from the AERIFY-1 and AERIFY-2 Phase 3 studies of itepekimab in COPD
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Aug 2023
- Due
- 31 Dec 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Results from the AERIFY-1 and AERIFY-2 studies are expected to be reported in 2025.”
What we found
Evidence strength A What the grades mean
Later filings show both AERIFY-1 and AERIFY-2 results were reported in 2025, with a May 2025 announcement; the exact day is not stated.
-
A Regeneron Pharmaceuticals 10-K filed 2026-02-04
“Reported that Phase 3 trial (AERIFY-1) in COPD met its primary endpoint; second Phase 3 trial (AERIFY-2) did not meet same primary endpoint” ✓ confirmed on the page
-
A Regeneron Pharmaceuticals 10-Q filed 2026-04-29
“in May 2025, we and Sanofi announced that one of two Phase 3 trials evaluating itepekimab in adults who were former smokers with inadequately controlled COPD did not meet its primary endpoint.” ✓ confirmed on the page
Market reaction: the shares moved +3.3% against the S&P 500 over the three sessions around the disclosure (3 Feb 2026 to 6 Feb 2026). What this measures
Checked 11 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- AERIFY-1 and AERIFY-2 Phase 3 study results for itepekimab
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Regeneron Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-REGN-006346 · Corrections policy